Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL
Extending Anticoagulation With Apixaban Reduces Recurrent VTE
Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care
Michael Chernew, PhD, Discusses Challenges in Oncology Management